Through our drug discovery platforms, we identify and develop new product candidates for significant unmet medical needs
Our biologics and small molecule chemistry drug discovery platforms augment our pipeline of clinical-stage product candidates. We leverage our multi-disciplinary team of scientific experts and our advanced understanding of the molecular mechanisms of disease to establish development paths for disease areas where significant unmet medical needs exist.
In April 2015, we transferred our gene therapy platform to MeiraGTx Limited, an independent clinical-stage company in which Kadmon retains a meaningful interest.
We have a fully human monoclonal antibody platform run by an experienced group of scientists. We are developing monoclonal antibodies as well as fusion proteins and bi-specific antibodies that we believe represent the next generation of cancer therapeutics.
Our most advanced candidate from this platform, KD035, is a proprietary anti angiogeneic antibody targeting VEGFR2, which inhibits the formation of new blood vessels, blocking blood supply to tumors.
We are also developing KD033, a novel anti PD L1/IL 15 fusion protein that combines the effects of two complementary immuno-oncology approaches to potentially achieve greater efficacy than single-agent therapy.
Small Molecule Chemistry
In addition to conducting traditional medicinal chemistry, we have licensed a proprietary chemical library (the ‘‘Chiromics’’ library) created through an innovative process of enzymatic catalysis. This new method of creating molecules permits the isolation of product candidates with novel chemical scaffolds that we believe will be able to hit targets that were previously difficult to address with traditional small molecule therapies.
We are leveraging our small molecule chemistry team’s expertise to build and expand our ROCK inhibitor platform. We have identified and are developing ROCK2 and pan-ROCK inhibitor compounds with varying specificity and solubility characteristics to treat specific autoimmune and fibrotic diseases, as well as blood-brain barrier penetrant ROCK2 inhibitors to treat neurodegenerative diseases.
In addition, our small molecule chemistry team develops inhibitors to glucose transport 1 (GLUT-1), a molecular target of the metabolic pathway that is associated with autoimmune diseases.